In last of 2019, the Centers for Disease Control and Prevention started monitoring the outbreak of a new corona virus, SARS-CoV-2, which causes the respiratory illness now known as COVID-19. Authorities first identified the virus in Wuhan, China. More than 82542 case of Corona virus in China at 31 March 2020. Health authorities have identified many other people with COVID-19 around the world. On 31 March 2020, the virus spread more than 750890 People in the World. The World Health Organization (WHO) has declared a public health emergency relating to COVID-19. Since then, this strain has been diagnosed in several residents of world. The CDC have advised that it is likely to spread to more people. COVID-19 has affected at least 213 countries or territories or areas. The first people with COVID-19 had links to an animal and seafood market. This fact suggested that animals initially transmitted the virus to humans. However, people with a more recent diagnosis had no connections with or exposure to the market, confirming that humans can pass the virus to each other. Corona viruses will infect most people at some time during their lifetime. Corona viruses can mutate effectively, which makes them so contagious. Information on the virus is scarce at present. In the past, respiratory conditions that develop from corona viruses, such as SARS and MERS, have spread through close contacts. On 17 February 2020, the Director-General of the WHO presented at a media briefing the following updates on how often the symptoms of COVID-19.However, while some viruses are highly contagious, it is less clear how rapidly corona viruses will spread. Symptoms vary from person-to-person with COVID-19. It may produce few or no symptoms. However, it can also lead to severe illness and may be fatal. On 11 March 2020, WHO declared Novel Corona virus Disease (COVID-19) outbreak as a Pandemic. Keywords: WHO, ICMR, SARS-CoV-2, Bats, Wuhan City, Pneumonia, Respiratory Infection, Pandemic
The main aim of the study was to determine the phytoconstituents present in Leaves of Leucas aspera. The present study was therefore carried out to evaluate the anti-ulcer activity of Hydroalcoholic (70% methanol) leaf extract of Leucas aspera in rats. The effect of Leucas aspera extract on gastric ulcer in rats in indomethacin induced gastric ulcers model and ethanol-induced models was studied using single dosing (100, 200 mg/kg) and repeated dosing (200 mg/kg for 5 days) approaches. Ranitidine (50 mg/kg) and cimetidine (100 mg/kg) were used as the standard drugs. Depending on the model, outcome measures were volume ulcer index. Data were analyzed using one-way analysis of variance and P<0.05 was considered as statistically significant. Leucas aspera significantly (P<0.001) reduced gastric ulcer, respectively, in indomethacin induced gastric ulcers model and ethanol-induced models at the 200 mg/kg dose, which is comparable to the standard drugs. 5 days pre-treatment with Leucas aspera 200 mg/kg exhibited significant (P<0.001) ulcer inhibition. Leucas aspera possesses both dose-dependent and time-dependent anti-ulcer effect in the two models. The oral median lethal dose (LD50) is estimated to be higher than 2000 mg/kg for the crude hydroalcoholic extract, and secondary metabolites such as flavonoids, tannins, and saponins were present. The findings of this study confirmed that Leucas aspera has anti-ulcer pharmacologic activity due to one or more of the secondary metabolites present in it. Therefore, this study validates its anti-ulcer use in Ethiopian folk medicine. Further investigations on isolation of specific phytochemicals and elucidating mechanisms of action are needed.
According to Biological Conservation Letter, more than 7,000 species of plants found in various ecosystems are said to be medicinal in the country. So, India is one of the world’s richest sources of medicinal and aromatic plants. Desmodium gangeticum is an important medicinal plant. It is commonly used in ayurvedic formulations for the treatment of various disorders. Phytochemical evaluations, pharmacogonostic evaluation, organoleptic characters, TLC profile was carried out to set them as diagnostic indices for the identification/validation of the raw material and standardization of the formulations. Preliminary phytochemical analysis showed the presence of active constituents which is necessary for the pharmacological activity. Organoleptic properties, phyto-chemical studies, powder analysis, showed the presence of adulteration in the powder. Majority of the antidepressant drugs improve depressive symptoms, but they exert multiple undesirable side effects. The search for more productive and well tolerated drugs is in progress. Phytochemical analysis of Desmodium gangeticum revealed the presence of alkaloids, phenols, flavonoids, Saponins, Steroids. Desmodium gangeticum is a well known medicinal plant as anti-inflammatory, antimicrobial and nephroprotective etc. It is a very good drug for urinogenital problems, hepatic problems, oxidative stress etc. The present study was depict to evaluate the antidepressant activity of hydroalcoholic extract of Desmodium gangeticum in mice. It was evaluated using the Tail Suspension Test (TST) and Forced Swimming Test (FST) in mice. Desmodium gangeticum (200 and 400 mg/kg) was administered orally in separate groups of Swiss albino mice weighing 20-25 for 14 days in TST and FST tests.. The Leaves extract of Desmodium gangeticum showed a dose dependant reduction in duration of immobility in mice. The dose of 400 mg/kg of Leaves extract of Desmodium gangeticum significantly reduced the immobility time of mice in both FST and TST. The effectual of extract was found to be similar to fluoxetine (20 mg mg/kg, po). It was found to be toxicologically safe with no deaths of mice when administered orally at the dose of 2000 mg/kg. From the current study, it can be concluded that the Leaves extract of Desmodium gangeticum possess dominant antidepressant activity as reveal by the TST and FST tests and is toxicologically safe.
The purpose of this research work was to formulate raft-forming chewable bilayer tablets of sodium alginate using a raft-forming agent along with gas-generating agents. Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralization capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as variables. Raft strength, acid neutralization capacity and drug release at 30 min were selected as responses.Tablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralization capacity and in vitro drug release of all factorial batches were found to be satisfactory. Prepared tablets were found to be pharmaceutically equivalent to the marketed product. It was concluded that raft-forming chewable bilayer tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux diseases. Keywords: Chewable bilayer tablet, Sodium alginate, Raft forming agent, Acid Neutralizing capacity
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.